Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636373 · ClinicalTrials.gov registry record · Phase 4
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
A Phase 4 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03636373: Clinical Trial Phase 4 study, sponsored by Rutgers, The State University of New Jersey.
NCT03636373 is a Phase 4 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03636373, a Phase 4 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.
Primary Outcome
Pain intensity in the most affected baseline joint measured by the numeric 0-10 Visual Analog Scale at 72 hours with 0 indicating no pain and 10 indicating intense pain. Higher score indicating a worse outcome.
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-10-25 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 4 |
Why NCT03636373 stopped before completion
NCT03636373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT03636373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03636373 about?
NCT03636373 is a clinical study titled "Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout". The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.
What is the current status of trial NCT03636373?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2019-10-25. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT03636373?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT03636373?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03636373's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI